Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: COPD
Interventions: Placebo, Fluticasone /salmeterol; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Bronchiectasis
Interventions: Ciprofloxacin (BAYQ3939) dry powder for inhalation, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 22
States / cities: Peoria, Arizona • Fountain Valley, California • La Jolla, California + 19 more

Conditions: Acute Pain
Interventions: Diclofenac Sodium Patch, Matching Placebo Patch; Drug
Lead sponsor: Cerimon Pharmaceuticals; Industry
Eligibility: 17 Years to 75 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Impaired Glucose Tolerance
Interventions: Sildenafil, Placebo, Hyperglycemic clamp, Euglycemic clamp; Drug · Diagnostic Test
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Covid19
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Athletic Performance, Recovery, Sleep
Interventions: Magnesium glycinate, Magnesium L-threonate, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
Interventions: AZ-3102, Placebo; Drug
Lead sponsor: Azafaros B.V.; Industry
Eligibility: 4 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Oakland, California • Minneapolis, Minnesota • Rochester, Minnesota + 2 more

Conditions: Postpartum Depression
Interventions: SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 27
States / cities: Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more

Conditions: Treatment-resistant Depression
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • San Rafael, California + 7 more

Conditions: Sleep Apnea, Obstructive
Interventions: Desipramine, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Subjects
Interventions: PF-06751979 single ascending dose, Placebo single dose, PF-06751979 multiple ascending dose, Placebo multiple dose, PF-06751979 multiple dose; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Glendale, California

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Lebrikizumab, Pirfenidone, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 54
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more

Conditions: Acute Ischemic Stroke
Interventions: TAK-755, Placebo; Biological · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 6 more

Conditions: Systemic Lupus Erythematosus
Interventions: GSK4527363, Placebo matching GSK4527363, Belimumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • Aurora, Colorado • Las Vegas, Nevada + 3 more

Conditions: Active Psoriatic Arthritis
Interventions: TILD, matching placebo injections; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 45
States / cities: Dothan, Alabama • Gilbert, Arizona • Glendale, Arizona + 41 more

Conditions: Fatty Liver, Insulin Resistance
Interventions: rosiglitazone, fenofibrate, placebo for rosiglitazone, placebo for fenofibrate; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
Interventions: Canagliflozin (JNJ-28431754), Sitagliptin, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more

Conditions: Painful Diabetic Peripheral Neuropathy
Interventions: pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 55
States / cities: Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Norovirus Acute Gastroenteritis
Interventions: mRNA-1403, mRNA-1405, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more

Conditions: Crohn's Disease, Complex Perianal Fistula
Interventions: Placebo, Darvadstrocel; Other · Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 22
States / cities: San Francisco, California • West Hollywood, California • New Haven, Connecticut + 17 more

Conditions: Sciatica
Interventions: CEP-37247, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 20
States / cities: La Mesa, California • Laguna Hills, California • Pasadena, California + 15 more

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo, Avonex®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Inherited Erythromelalgia
Interventions: PF-05089771, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Matching placebo; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 50 more

Search by objective public record fields.

Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD

Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion

Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis

Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)

UCLA Magnesium Formulation Athlete Study

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Study of TAK-755 in Adults With Acute Ischemic Stroke

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Insulin Resistance in Non-alcoholic Fatty Liver Disease

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria